Literature DB >> 1972019

Sequence of two alleles responsible for Gaucher disease.

C M Hong1, T Ohashi, X J Yu, S Weiler, J A Barranger.   

Abstract

Enzymatically amplified RNA transcripts were used to analyze the full coding region of the glucocerebrosidase gene from Gaucher disease patients. Two previously undescribed mutations were identified. One mutation consists of a single-base substitution in three different codons: codon 444, Leu (CTG) to Pro (CCG); codon 456, Ala (GCT) to Pro (CCT); and codon 460, Val (GTG) to Val (GTC). This mutant is called "pseudo pattern" (psi) because it is identical in sequence to a small region of the pseudogene in exon 10 (Horowitz et al., 1989). The other new mutation is a single-base substitution (C to T) resulting in the substitution of Cys for Arg in codon 463. These mutations in the human gene were duplicated in wild-type cDNA and expressed in 3T3 cells. The human mutant proteins were isolated by immunoaffinity and shown to have altered enzymatic properties demonstrating the causality of these two allelic mutations for Gaucher disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1972019     DOI: 10.1089/dna.1990.9.233

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  22 in total

1.  Development of genomic DNA reference materials for genetic testing of disorders common in people of ashkenazi jewish descent.

Authors:  Lisa Kalman; Jean Amos Wilson; Arlene Buller; John Dixon; Lisa Edelmann; Louis Geller; William Edward Highsmith; Leonard Holtegaard; Ruth Kornreich; Elizabeth M Rohlfs; Toby L Payeur; Tina Sellers; Lorraine Toji; Kasinathan Muralidharan
Journal:  J Mol Diagn       Date:  2009-10-08       Impact factor: 5.568

2.  Characteristics of gene mutations among 32 unrelated Japanese Gaucher disease patients: absence of the common Jewish 84GG and 1226G mutations.

Authors:  H Ida; K Iwasawa; H Kawame; O M Rennert; K Maekawa; Y Eto
Journal:  Hum Genet       Date:  1995-06       Impact factor: 4.132

3.  Role of pH in determining the cell-type-specific residual activity of glucocerebrosidase in type 1 Gaucher disease.

Authors:  S van Weely; M van den Berg; J A Barranger; M C Sa Miranda; J M Tager; J M Aerts
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

Review 4.  Gaucher disease as a paradigm of current issues regarding single gene mutations of humans.

Authors:  E Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

5.  Congenital insensitivity to pain with anhidrosis: novel mutations in the TRKA (NTRK1) gene encoding a high-affinity receptor for nerve growth factor.

Authors:  S Mardy; Y Miura; F Endo; I Matsuda; L Sztriha; P Frossard; A Moosa; E A Ismail; A Macaya; G Andria; E Toscano; W Gibson; G E Graham; Y Indo
Journal:  Am J Hum Genet       Date:  1999-06       Impact factor: 11.025

6.  A new glucocerebrosidase-gene missense mutation responsible for neuronopathic Gaucher disease in Japanese patients.

Authors:  H Kawame; Y Eto
Journal:  Am J Hum Genet       Date:  1991-12       Impact factor: 11.025

7.  Prevalence of nine mutations among Jewish and non-Jewish Gaucher disease patients.

Authors:  M Horowitz; G Tzuri; N Eyal; A Berebi; E H Kolodny; R O Brady; N W Barton; A Abrahamov; A Zimran
Journal:  Am J Hum Genet       Date:  1993-10       Impact factor: 11.025

8.  Phenotypic and genotypic heterogeneity in gaucher disease: Implications for genetic counseling.

Authors:  E Sidransky; E I Ginns
Journal:  J Genet Couns       Date:  1994-03       Impact factor: 2.537

9.  Gaucher disease: heterologous expression of two alleles associated with neuronopathic phenotypes.

Authors:  M E Grace; A Berg; G S He; L Goldberg; M Horowitz; G A Grabowski
Journal:  Am J Hum Genet       Date:  1991-09       Impact factor: 11.025

10.  Position of the sulfhydryl group and the disulfide bonds of human glucocerebrosidase.

Authors:  Y Lee; H Kinoshita; G Radke; S Weiler; J A Barranger; J M Tomich
Journal:  J Protein Chem       Date:  1995-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.